38.06 USD
▼-0.80-2.06%
盘后 37.80 -0.68%
2026-09-15
市值
$2.64B
市盈率
—
EPS
-2.99
股息率
—
52 周区间
20.65 – 43.25
成交量
1.75M
Beta
-2.33
目标价
59.11
52W 低 20.6552W 高 43.25
价格走势
公司简介
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a...